ライフサイエンスコーパス: vasoactive intestinal polypeptide

1 P) as a second messenger (e.g., secretin and vasoactive intestinal polypeptide).

2 toxin-insensitive G(s)-coupled receptors for vasoactive intestinal polypeptide.

3 tion in response to sodium nitroprusside and vasoactive intestinal polypeptide.

4 Rs that do not distinguish between PACAP and vasoactive intestinal polypeptide.

5 a response not elicited by stimulation with vasoactive intestinal polypeptide.

6 sequence homology with both PACAP-27/38 and vasoactive intestinal polypeptide.

7 injured unmyelinated afferents labeled with vasoactive intestinal polypeptide.

8 rtical interneurons express either Reelin or vasoactive intestinal polypeptide.

9 AC receptor homo-oligomers were modulated by vasoactive intestinal polypeptide.

10 dal cells and GABA interneurons coexpressing vasoactive intestinal polypeptide.

11 Vasoactive intestinal polypeptide (60 nmol/L), acetylcho

12 ehavior, combined with genetic disruption of vasoactive intestinal polypeptide, a key SCN signaling m

13 al afferents, and contains neurons producing vasoactive intestinal polypeptide and gastrin-releasing

14 er, GTP gamma S binding induced by CCK-8 and vasoactive intestinal polypeptide and the binding capaci

15 The VPAC(1) and VPAC(2) receptors for vasoactive intestinal polypeptide and the PAC(1) recepto

16 ceptor or of the neuropeptides somatostatin, vasoactive intestinal polypeptide, and choleocystokinin.

17 s variant gene 1, substance P, somatostatin, vasoactive intestinal polypeptide, and parvalbumin.

18 neurons contained the inhibitory transmitter vasoactive intestinal polypeptide, and some were immunor

19 nolol, methysergide, substance P antagonist, vasoactive intestinal polypeptide antagonist, apamin, an

20 found in SCN cells, arginine vasopressin and vasoactive intestinal polypeptide appeared to be in cont

21 and the receptors for prostaglandin E(2) and vasoactive intestinal polypeptide, are not expressed or

22 AC1-VPAC2 hetero-oligomers were modulated by vasoactive intestinal polypeptide binding, whereas the s

23 co-localize with either cholecystokinin- or vasoactive intestinal polypeptide, but does with vasopre

24 n at least acetylcholine, adrenergic agents, vasoactive intestinal polypeptide, calcitonin gene-relat

25 pressing cyclooxygenase-2 (22%, p < 0.05) or vasoactive intestinal polypeptide-containing interneuron

26 unctions such as motility and secretion (eg, vasoactive intestinal polypeptide, cystic fibrosis trans

27 It has been demonstrated that vasoactive intestinal polypeptide, epidermal growth fact

28 We report that vasoactive intestinal polypeptide, epidermal growth fact

29 re, we used a transgenic mouse line in which vasoactive intestinal polypeptide-expressing (VIP+) GABA

30 at in contrast to somatostatin-expressing or vasoactive intestinal polypeptide-expressing interneuron

31 tory neurons reduced their activity, whereas vasoactive intestinal polypeptide-expressing interneuron

32 ubstance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide, galanin, somatostatin

33 bodies with immunoreactive (IR) vasopressin, vasoactive intestinal polypeptide, gastrin-releasing pep

34 Immunostaining for vasoactive intestinal polypeptide-immunoreactive parasym

35 Vasoactive intestinal polypeptide immunoreactivity was f

36 signaling pathways induced by kisspeptin and vasoactive intestinal polypeptide in GnRH neuronal cell

37 for the specification of neuropeptide Y and vasoactive intestinal polypeptide, indicating that a sub

38 Vasoactive intestinal polypeptide may be the molecule th

39 ndin, calretinin, parvalbumin, somatostatin, vasoactive intestinal polypeptide, neuropeptide Y, or ch

40 Immunoreactivity for vasoactive intestinal polypeptide, nitric oxide synthase

41 Vasoactive intestinal polypeptide operated via protein k

42 ons, but not nonpyramidal neurons containing vasoactive intestinal polypeptide or neuropeptide Y.

43 light acting weakly upon a strongly rhythmic vasoactive intestinal polypeptide oscillation can explai

44 Although locomotion-induced vasoactive intestinal polypeptide positive (VIP) interne

45 nitric oxide synthase (eNOS)-expressing and vasoactive intestinal polypeptide-positive enteric neuro

46 inergic, adrenergic, and nitrergic axons and vasoactive intestinal polypeptide-positive terminals, so

47 ealed an abnormal number and distribution of vasoactive intestinal polypeptide-producing neurons, sug

48 d by agonists such as prostaglandin E(2) and vasoactive intestinal polypeptide, promotes proliferatio

49 function, including cholinergic, adrenergic, vasoactive intestinal polypeptide, purinergic, androgen,

50 The transcriptional repressor for rat vasoactive intestinal polypeptide receptor 1 (VIPR-RP) i

51 Here, we show that subtypes of human vasoactive intestinal polypeptide receptors (VPAC1 and V

52 in, or with thyrotropin releasing hormone or vasoactive intestinal polypeptide resulted in abundant e

53 Acetylcholine, isoproterenol, and vasoactive intestinal polypeptide significantly stimulat

54 phorbol ester, epidermal growth factor, and vasoactive intestinal polypeptide stimulated p38 MAP kin

55 e exchange of action potentials that release vasoactive intestinal polypeptide, striking a compromise

56 gene-related peptide, tyrosine hydroxylase, vasoactive intestinal polypeptide, substance P, corticot

57 y preabsorption of PACAP-27/38 antisera with vasoactive intestinal polypeptide, suggesting that a sub

58 In contrast, vasoactive intestinal polypeptide-, TK-, choline acetylt

59 oxylase, neuronal nitric oxide synthase, and vasoactive intestinal polypeptide to visualize neural el

60 de for two other members of this family, the vasoactive intestinal polypeptide type 1 and calcitonin

61 The vasoactive intestinal polypeptide type-1 (VPAC(1)) recep

62 (MT), corticotropin-releasing hormone (CRH), vasoactive intestinal polypeptide, tyrosine hydroxylase,

63 We demonstrate that interneurons expressing vasoactive intestinal polypeptide (VIP(+)) play a causal

64 Here, we show that interneurons expressing vasoactive intestinal polypeptide (VIP(+)) regulate the

65 of two neuropeptides synthesized in the SCN, vasoactive intestinal polypeptide (VIP) and arginine vas

66 hat type 3 IS (IS3) cells that coexpress the vasoactive intestinal polypeptide (VIP) and calretinin c

67 th light microscopic immunocytochemistry for vasoactive intestinal polypeptide (VIP) and cytoarchitec

68 -dependent coupling process mediated by both vasoactive intestinal polypeptide (VIP) and GABAA signal

69 The neuropeptide vasoactive intestinal polypeptide (VIP) and its VPAC2 re

70 also simulated clock phase shifts induced by vasoactive intestinal polypeptide (VIP) and matched expe

71 opalatine ganglion, which appears to utilize vasoactive intestinal polypeptide (VIP) and nitric oxide

72 an serous cells secrete fluid in response to vasoactive intestinal polypeptide (VIP) and other agents

73 adenomas, we investigated the expression of vasoactive intestinal polypeptide (VIP) and PACAP bindin

74 s this cyclic information to GnRH neurons is vasoactive intestinal polypeptide (VIP) and that it may

75 een the pelvic visceral afferent transmitter vasoactive intestinal polypeptide (VIP) and the delta-op

76 Vasoactive intestinal polypeptide (VIP) and the VIP rece

77 e used to ascertain the relationship between vasoactive intestinal polypeptide (VIP) and tyrosine hyd

78 L-arginine methyl ester (L-NAME), but not by vasoactive intestinal polypeptide (VIP) antiserum, guane

79 r AVD is a redundant system in which ACh and vasoactive intestinal polypeptide (VIP) are co-released

80 recent data implicating the neurotransmitter vasoactive intestinal polypeptide (VIP) as the key synch

81 racellular cAMP, was sufficient to stimulate vasoactive intestinal polypeptide (VIP) biosynthesis at

82 Extending the secretin-vasoactive intestinal polypeptide (VIP) chimeric recepto

83 ) of an antibody raised by immunization with vasoactive intestinal polypeptide (VIP) cleaved this pep

84 , we investigated whether the projections of vasoactive intestinal polypeptide (VIP) from the SCN to

85 olar infusion of the VPAC1/2 receptor ligand vasoactive intestinal polypeptide (VIP) had no effect on

86 Vasoactive intestinal polypeptide (VIP) has also been sh

87 The peptide neurotransmitter vasoactive intestinal polypeptide (VIP) has several impo

88 e cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) have been found

89 e cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) immunoreactive (

90 ked sexual dimorphism in the distribution of vasoactive intestinal polypeptide (VIP) immunoreactive f

91 K), and receive input from galanin (GAL) and vasoactive intestinal polypeptide (VIP) immunoreactive f

92 Recent evidence suggests a role for vasoactive intestinal polypeptide (VIP) in active vasodi

93 d determine the role of mast cells (MCs) and vasoactive intestinal polypeptide (VIP) in barrier regul

94 were immunoreactive for vasopressin (AVP) or vasoactive intestinal polypeptide (VIP) in wild type and

95 Vasodilatory nerve fibers containing vasoactive intestinal polypeptide (VIP) innervate choroi

96 and alpha5-knockout mice, lower activity of vasoactive intestinal polypeptide (VIP) interneurons res

97 Vasoactive intestinal polypeptide (VIP) is a neuropeptid

98 Vasoactive intestinal polypeptide (VIP) is an intrinsic

99 Vasoactive intestinal polypeptide (VIP) is distributed i

100 In mammals, vasoactive intestinal polypeptide (VIP) is known to have

101 Vasoactive intestinal polypeptide (VIP) is released from

102 ow that a class of interneurons that express vasoactive intestinal polypeptide (VIP) mediates disinhi

103 Previous data suggested vasoactive intestinal polypeptide (VIP) might be contain

104 upled via gamma-aminobutyric acid (GABA) and vasoactive intestinal polypeptide (VIP) neurotransmitter

105 The effects of vasoactive intestinal polypeptide (VIP) on isolated para

106 ssion and odor detection performance require vasoactive intestinal polypeptide (VIP) or its receptor

107 that contained arginine vasopressin (AVP) or vasoactive intestinal polypeptide (VIP) or neither.

108 There is evidence that vasoactive intestinal polypeptide (VIP) participates in

109 nd these constituted a sub-population of the vasoactive intestinal polypeptide (VIP) positive cells.

110 ampal neurons in culture to demonstrate that vasoactive intestinal polypeptide (VIP) promotes neurona

111 All splice variants of PAC1 were found, but vasoactive intestinal polypeptide (VIP) receptor (VPAC)

112 The type 1 vasoactive intestinal polypeptide (VIP) receptor gene is

113 Both secretin and vasoactive intestinal polypeptide (VIP) receptors are re

114 Vasoactive intestinal polypeptide (VIP) relaxes smooth m

115 Vasoactive intestinal polypeptide (VIP) signaling is cri

116 ne hydroxylase, nitric oxide synthetase, and vasoactive intestinal polypeptide (VIP) to detect neural

117 Neurones immunoreactive for vasoactive intestinal polypeptide (VIP) were studied in

118 Strikingly, vasoactive intestinal polypeptide (VIP), a neuropeptide

119 Paradoxically, we found that vasoactive intestinal polypeptide (VIP), a neuropeptide

120 ansmission was simulated via the addition of vasoactive intestinal polypeptide (VIP), a pelvic viscer

121 OR myenteric neurons were immunoreactive for vasoactive intestinal polypeptide (VIP), and about 31% w

122 ce labeling for nitric oxide synthase (NOS), vasoactive intestinal polypeptide (VIP), and choline ace

123 rneurons expressing neuropeptide Y (NPY) and vasoactive intestinal polypeptide (VIP), and the numeric

124 ne-related peptide (CGRP), substance P (SP), vasoactive intestinal polypeptide (VIP), and tyrosine hy

125 sine hydroxylase (TH), neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP), calcitonin gene

126 e (nNOS), choline acetyl transferase (ChAT), vasoactive intestinal polypeptide (VIP), calcitonin gene

127 presence and colocalization of the peptides vasoactive intestinal polypeptide (VIP), calcitonin-gene

128 e cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP), on ECL cell pro

129 Vasoactive intestinal polypeptide (VIP), pituitary adeny

130 r GnIH inhibits the action of kisspeptin and vasoactive intestinal polypeptide (VIP), positive regula

131 The pattern of distribution of vasoactive intestinal polypeptide (VIP)- and tyrosine hy

132 the nucleus characterized by a population of vasoactive intestinal polypeptide (VIP)-containing neuro

133 circuit in frontal cortex that originates in vasoactive intestinal polypeptide (VIP)-expressing inter

134 , but not that of somatostatin-expressing or vasoactive intestinal polypeptide (VIP)-expressing inter

135 OS)-, choline acetyltransferase (ChAT)-, and vasoactive intestinal polypeptide (VIP)-immunoreactiviti

136 stance P (SP)-IR varicosities and 9 +/- 1.3% vasoactive intestinal polypeptide (VIP)-IR varicosities

137 ion-induced release of substance P (SP)- and vasoactive intestinal polypeptide (VIP)-like immunoreact

138 piperazinium iodide (DMPP), and neuropeptide vasoactive intestinal polypeptide (VIP).

139 erated against vertebrate retinal opsins and vasoactive intestinal polypeptide (VIP).

140 ent manner by dorsal AH neurons that produce vasoactive intestinal polypeptide (VIP).

141 the structurally similar mammalian peptide, vasoactive intestinal polypeptide (VIP).

142 zed the population, phenocopying the loss of vasoactive intestinal polypeptide (VIP).

143 ot for parvalbumin (PV), calretinin (CR), or vasoactive intestinal polypeptide (VIP).

144 d was expressed in 7-12% of cells containing vasoactive intestinal polypeptide (VIP).

145 N, physiological evidence suggests that only vasoactive intestinal polypeptide (VIP)/gastrin-releasin

146 ATP (1 mM), vasoactive intestinal polypeptide (VIP, 0.01-0.25 microM

147 Vasoactive intestinal polypeptide (VIP, 1 nmol) had no s

148 The GsPCR agonist, vasoactive intestinal polypeptide (VIP; 100 nM), rapidly

149 s of somatostatin(+) (SST) (MGE-derived) and vasoactive intestinal polypeptide(+) (VIP) (CGE-derived)

150 ed on immunocytochemistry, that synthesis of vasoactive intestinal polypeptide was increased upon lid

151 acetyltransferase, and substance P, whereas vasoactive intestinal polypeptide was more abundant in v